Signaling sphingolipids are biomarkers for atopic dermatitis prone to disseminated viral infections
Evgeny Berdyshev(National Jewish Health), Donald Y.M. Leung(Boston Children's Hospital), Elena Goleva(National Jewish Health), Mark K. Slifka(Oregon Health & Science University), Brittany Richers(National Jewish Health), Lisa A. Beck(University of Rochester Medicine), Anna Sofia Bronoff(National Jewish Health), Jon M. Hanifin(Oregon Health & Science University), Patricia A. Taylor(National Jewish Health), Joanne E. Streib(National Jewish Health), Keli Johnson(Rho (United States)), Gloria L. David(Rho (United States)), Irina Bronova(National Jewish Health), Miguel Villarreal(Rho (United States)), Kathryn A. Vang(National Jewish Health)
Cited by 16
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k